Literature DB >> 17725386

Production, characterization, and functional analysis of newly established CD99 monoclonal antibodies MT99/1 and MT99/2.

Panida Khunkaewla1, Sawitree Chiampanichayakul, Umpa Yasamut, Supansa Pata, Watchara Kasinrerk.   

Abstract

The leukocyte surface molecule CD99 is an integral membrane glycoprotein encoded by the E2/MIC2 gene. This molecule is broadly expressed on cells of the hematopoietic system and displays two surface forms, a long 32 kDa form and a short 28 kDa form. While the complete function of the CD99 molecule is unclear, it has been reported to be involved in regulation of cell adhesion, migration, and apoptosis. Thus, several CD99 monoclonal antibodies (MAbs) have been generated for biochemical and functional studies of the CD99 molecule. In the present study two CD99 MAbs, MT99/1 and MT99/2, were produced. The MAbs recognized different epitopes of the CD99 molecule. MAb MT99/1, but not MT99/2, was appropriate for biochemical characterization. Binding of MAb MT99/1 with its epitope led to the induction of cell adhesion and apoptosis. The generated MAbs can be used for future study of the function and mechanism of the CD99 molecule, including its role in the immune system, and may have application in tumor diagnosis and treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17725386     DOI: 10.1089/hyb.2007.0504

Source DB:  PubMed          Journal:  Hybridoma (Larchmt)        ISSN: 1554-0014


  8 in total

1.  Protein expression and gene promoter hypermethylation of CD99 in transitional cell carcinoma of urinary bladder.

Authors:  Yanhua Xuan; Seokhyung Kim; Zhenhua Lin
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-09       Impact factor: 4.553

2.  CD99 is upregulated in placenta and astrocytomas with a differential subcellular distribution according to the malignancy stage.

Authors:  Ursula Úrias; Suely K N Marie; Miyuki Uno; Roseli da Silva; Mariá M Evagelinellis; Otavia L Caballero; Brian J Stevenson; Wilson A Silva; Andrew J Simpson; Sueli M Oba-Shinjo
Journal:  J Neurooncol       Date:  2014-05-06       Impact factor: 4.130

3.  A modified hybridoma technique for production of monoclonal antibodies having desired isotypes.

Authors:  Napaporn Apiratmateekul; Ponrat Phunpae; Watchara Kasinrerk
Journal:  Cytotechnology       Date:  2009-07-29       Impact factor: 2.058

4.  High-valency Anti-CD99 Antibodies Toward the Treatment of T Cell Acute Lymphoblastic Leukemia.

Authors:  Larizbeth A Romero; Takamitsu Hattori; Mohamed A E Ali; Gayatri Ketavarapu; Akiko Koide; Christopher Y Park; Shohei Koide
Journal:  J Mol Biol       Date:  2021-12-24       Impact factor: 5.469

5.  Association of CD99 short and long forms with MHC class I, MHC class II and tetraspanin CD81 and recruitment into immunological synapses.

Authors:  Supansa Pata; Pavel Otáhal; Tomáš Brdička; Witida Laopajon; Kodchakorn Mahasongkram; Watchara Kasinrerk
Journal:  BMC Res Notes       Date:  2011-08-13

6.  Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma.

Authors:  Emily Capone; Enza Piccolo; Imma Fichera; Paolo Ciufici; Daniela Barcaroli; Arturo Sala; Vincenzo De Laurenzi; Valentina Iacobelli; Stefano Iacobelli; Gianluca Sala
Journal:  Oncotarget       Date:  2017-07-22

7.  Interaction of CD99 and its ligand upregulates IL-6 and TNF-α upon T cell activation.

Authors:  Nuchjira Takheaw; Papawadee Earwong; Witida Laopajon; Supansa Pata; Watchara Kasinrerk
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

8.  The presence of membrane bound CD99 ligands on leukocyte surface.

Authors:  Nuchjira Takheaw; Supansa Pata; Witida Laopajon; Sittiruk Roytrakul; Watchara Kasinrerk
Journal:  BMC Res Notes       Date:  2020-10-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.